These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8130888)

  • 21. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol.
    Malberti F; Surian M; Cosci P
    Kidney Int Suppl; 1993 Jun; 41():S125-30. PubMed ID: 8320905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Low dosage intravenous calcitriol bolus therapy in chronic hemodialysis patients].
    Neyer U; Wöss E; Drexel H
    Acta Med Austriaca; 1994; 21(5):129-32. PubMed ID: 7709710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating 1,25-dihydroxycholecalciferol after intravenous injections of 1 alpha-hydroxycholecalciferol in patients on regular haemodialysis.
    Papapoulos SE; vd Berg H; Frölich M; Valentijn RM
    Nephrol Dial Transplant; 1988; 3(5):647-50. PubMed ID: 3146722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
    Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
    Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol.
    Cannella G; Bonucci E; Rolla D; Ballanti P; Moriero E; De Grandi R; Augeri C; Claudiani F; Di Maio G
    Kidney Int; 1994 Oct; 46(4):1124-32. PubMed ID: 7861707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of sex and age on biochemical bone metabolism parameters.
    Resch H; Pietschmann P; Kudlacek S; Woloszczuk W; Krexner E; Bernecker P; Willvonseder R
    Miner Electrolyte Metab; 1994; 20(3):117-21. PubMed ID: 7815999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
    Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
    Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in calciotrophic hormones and biochemical markers of bone turnover in normal human pregnancy.
    Gallacher SJ; Fraser WD; Owens OJ; Dryburgh FJ; Logue FC; Jenkins A; Kennedy J; Boyle IT
    Eur J Endocrinol; 1994 Oct; 131(4):369-74. PubMed ID: 7921225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D deficiency amongst Pakistani women in Oslo.
    Brunvand L; Haug E
    Acta Obstet Gynecol Scand; 1993 May; 72(4):264-8. PubMed ID: 8389512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients.
    Marco MP; Martínez I; Amoedo ML; Borràs M; Saracho R; Almirall J; Fibla J; Fernández E
    Kidney Int; 1999 Oct; 56(4):1349-53. PubMed ID: 10504487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
    Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
    Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis.
    Ljunghall S; Althoff P; Fellström B; Marjanovic B; Nisell J; Weiss L; Wide L
    Nephron; 1990; 55(4):380-5. PubMed ID: 2392190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
    Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
    Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis.
    Pietschmann P; Resch H; Krexner E; Woloszczuk W; Willvonseder R
    Acta Med Austriaca; 1991; 18(5):114-6. PubMed ID: 1796722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis.
    Sahota O; Mundey MK; San P; Godber IM; Lawson N; Hosking DJ
    Bone; 2004 Jul; 35(1):312-9. PubMed ID: 15207772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics.
    Lu KC; Shieh SD; Chyr SH; Lin SH; Li BL; Diang LK; Chen WQ; Lin YF
    Diabetes Res; 1993; 22(3):97-104. PubMed ID: 8076446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.